Homologous Recombination Deficiency (HRD) in Cutaneous Oncology
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms241310771 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Favour A Akinjiyan und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, Department of Medicine, Washington University in Saint Louis, St. Louis, MO 63130, USA. Hauptthemen laut MEDLINE: Carcinoma, Squamous Cell, Skin Neoplasms, Melanoma, Ovarian Neoplasms. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 83 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Skin cancers, including basal cell carcinoma (BCC), cutaneous squamous cell carcinoma (SCC), and melanoma, are the most common malignancies in the United States. Loss of DNA repair pathways in the skin plays a significant role in tumorigenesis. In recent years, targeting DNA repair pathways, particularly homologous recombination deficiency (HRD), has emerged as a potential therapeutic approach in cutaneous malignancies. This review provides an overview of DNA damage and repair pathways, with a focus on HRD, and discusses major advances in targeting these pathways in skin cancers. Poly(ADP-ribose) polymerase (PARP) inhibitors have been developed to exploit HRD in cancer cells. PARP inhibitors disrupt DNA repair mechanisms by inhibiting PARP enzymatic activity, leading to the accumulation of DNA damage and cell death. The concept of synthetic lethality has been demonstrated in HR-deficient cells, such as those with BRCA1/2 mutations, which exhibit increased sensitivity to PARP inhibitors. HRD assessment methods, including genomic scars, RAD51 foci formation, functional assays, and BRCA1/2 mutation analysis, are discussed as tools for identifying patients who may benefit from PARP inhibitor therapy. Furthermore, HRD has been implicated in the response to immunotherapy, and the combination of PARP inhibitors with immunotherapy has shown promising results. The frequency of HRD in melanoma ranges from 18% to 57%, and studies investigating the use of PARP inhibitors as monotherapy in melanoma are limited. Further research is warranted to explore the potential of PARP inhibition in melanoma treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Medical Oncology, Department of Medicine, Washington University in Saint Louis, St. Louis, MO 63130, USA.
- CARIS Life Sciences, Irving, TX 75039, USA.
- Moores Cancer Center, University of California San Diego, La Jolla, CA 92093, USA.
ORCID-Profile: Favour A Akinjiyan, Omar H Butt
Zitieren
APA
Akinjiyan, F. A., Morecroft, R., Phillipps, J., Adeyelu, T., Elliott, A., Park, S. J., Butt, O. H., Zhou, A. Y., & Ansstas, G. (2023). Homologous Recombination Deficiency (HRD) in Cutaneous Oncology. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms241310771
Vancouver
Akinjiyan FA, Morecroft R, Phillipps J, Adeyelu T, Elliott A, Park SJ, et al. Homologous Recombination Deficiency (HRD) in Cutaneous Oncology. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms241310771
BibTeX
@article{Akinjiyan2023,
author = {Akinjiyan, Favour A and Morecroft, Renee and Phillipps, Jordan and Adeyelu, Tolulope and Elliott, Andrew and Park, Soo J and Butt, Omar H and Zhou, Alice Y and Ansstas, George},
title = {Homologous Recombination Deficiency (HRD) in Cutaneous Oncology},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms241310771}
}
EUVIMED